Mainz, Germany
Mainz, Germany
SEARCH FILTERS
Time filter
Source Type

Patent
Biontech Cell&Gene Therapies GmbH and Ganymed Pharmaceuticals | Date: 2017-02-08

The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.


Patent
Ganymed Pharmaceuticals | Date: 2017-05-24

The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of colorectal, in particular colonic, and gastric tumor tissues and colorectal, in particular colonic, and gastric tissues, and which represent targets for therapy or diagnosis of such tumor diseases in a subject.


Patent
Ganymed Pharmaceuticals | Date: 2016-09-06

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer.


Patent
Ganymed Pharmaceuticals | Date: 2016-09-22

The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which said genetic products that are expressed in association with a tumor are expressed in aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor.


Patent
Ganymed Pharmaceuticals | Date: 2016-01-28

Disclosed is a method of diagnosing and treating a head neck cancer characterized by expressing a tumor-associated antigen having the amino acid sequence shown in SEQ ID NO:4. The method comprises treating the so-affected patient with an antibody which specifically binds to an extracellular portion of said tumor-associated antigen having the amino acid sequence of SEQ ID NO: 4.


Patent
Ganymed Pharmaceuticals | Date: 2016-06-01

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor- related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.


Patent
Ganymed Pharmaceuticals and Johannes Gutenberg University Mainz | Date: 2016-07-08

The invention relates to the treatment and/or prevention of tumor diseases associated with cells expressing CLDN6, in particular cancer and cancer metastasis using antibodies which bind to CLDN6. The present application demonstrates that the binding of antibodies to CLDN6 on the surface of tumor cells is sufficient to inhibit growth of the tumor and to prolong survival and extend the lifespan of tumor patients. Furthermore, binding of antibodies to CLDN6 is efficient in inhibiting growth of CLDN6 positive germ cell tumors such as teratocarcinomas or embryonal carcinomas, in particular germ cell tumors of the testis.


Patent
Ganymed Pharmaceuticals and Johannes Gutenberg University Mainz | Date: 2016-04-20

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing Claudin-6 (CLDN6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.


Patent
Ganymed Pharmaceuticals and Johannes Gutenberg University Mainz | Date: 2016-08-08

The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.


Patent
Ganymed Pharmaceuticals and Johannes Gutenberg University Mainz | Date: 2016-03-21

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.

Loading Ganymed Pharmaceuticals collaborators
Loading Ganymed Pharmaceuticals collaborators